Herman Waldmann: Timeline of key events
Mouseover the event title for a more detailed description of the event (if available). To search for particular terms in the description of the event enter the term in the box below 'Event' on the table and press 'enter'. Alternatively use the dropdown lists to filter by Person, Place or Science. Click here to clear the filter.
|1991||The first MS patient is given Campath-1H||Waldmann, hale, Compston||Cambridge University||Campath|
|1993||The rights to Campath are assigned to the British Technology Group (BTG).||Waldmann||Cambridge University||Campath|
|1994||Waldmann moves to Oxford University.||Waldmann||Oxford University||Campath|
|1994||The TAC relocates to Oxford.||Hale, Waldmann||Oxford University||Campath|
|1997||Small scale tests launched with Campath-1H for organ transplant patients.||Waldmann, Calne, Friend||Cambridge University||Campath|
|1998||Analysis of 29 MS patients given MS indicate Campath-1H might be more effective if given earlier in the course of the disease.||Compston, Coles, Waldmann, Hale||Cambridge University||Campath|
|2011||Positive results from trials using Campath-1H for organ transplant patients||Waldmann, Calne||Cambridge University||Campath|
|Sep 2013||Campath-1H gains marketing approval for the treatment of MS.||Waldmann, Compston, Coles||Cambridge University||Campath|
|17 Sep 2013||European Commission approved Alemtuzumab (Lemtrada) for MS treatment||Compston, Coles, Waldmann||Cambridge University, Sanofi||Monoclonal antibodies, Campath|
The first MS patient is given Campath-1H
The rights to Campath are assigned to the British Technology Group (BTG).
Waldmann moves to Oxford University.
The TAC relocates to Oxford.
Small scale tests launched with Campath-1H for organ transplant patients.
Analysis of 29 MS patients given MS indicate Campath-1H might be more effective if given earlier in the course of the disease.
Positive results from trials using Campath-1H for organ transplant patients
Campath-1H gains marketing approval for the treatment of MS.
17 Sep 2013
European Commission approved Alemtuzumab (Lemtrada) for MS treatment